GPT and tuberculosis: Although INH is a first-line drug that is used to treat tuberculosis, approximately 10% of INH-treated patients exhibit upregulated (≥3× the upper limit of normal [ULN]) activity of alanine transaminase (ALT), and approximately 1% of INH-treated patients exhibit even greater upregulated ALT activity (>5× ULN) [46].